Immunotherapy for patients with EGFR-TKI-resistant non-small-cell lung cancer: Potential mechanisms, efficacy...

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Immunotherapy has transformed advanced non-small-cell lung cancer (NSCLC) treatment.
• Its role in epidermal growth factor receptor (EGFR)-mutant NSCLC post-tyrosine kinase inhibitor (TKI) therapy is complex and varies significantly.
• Tumor microenvironment (TME) remodeling under EGFR-TKI selective pressure influences treatment response.

Purpose of the Study:

• To review the TME's evolution during and after EGFR-TKI treatment in NSCLC.
• To summarize clinical data on immunotherapy efficacy following EGFR-TKI resistance.
• To discuss biomarkers and novel strategies for optimizing immunotherapy in EGFR-mutant NSCLC.

Main Methods:

• Literature review of TME dynamics during EGFR-TKI treatment and resistance.
• Synthesis of current clinical evidence on immunotherapy post-TKI failure.
• Analysis of predictive biomarkers and emerging therapeutic approaches.

Main Results:

• EGFR-TKI treatment dynamically alters the TME, impacting subsequent immunotherapy response.
• Heterogeneity in treatment outcomes is observed in EGFR-mutant NSCLC patients after TKI failure.
• Specific biomarkers and combination therapies show potential for improved outcomes.

Conclusions:

• Understanding TME evolution is crucial for predicting immunotherapy response in EGFR-mutant NSCLC.
• Identifying patient subgroups likely to benefit from immunotherapy post-TKI failure is key.
• Optimizing treatment strategies requires integrating mechanistic insights with clinical data.